Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: health – Page 69

Metformin and the TAME trial: a conversation with Nir Barzilai and Brad Stanfield

In this interview, hosted by Nicolás Cherñavsky, Nir Barzilai and Brad Stanfield discuss metformin, whether or not to use it in non-diabetic patients to slow aging, and the TAME trial.

Nir Barzilai is president of the Academy of Health and Lifespan Research (https://www.ahlresearch.org/), and Brad Stanfield is a primary care physician in Auckland (New Zealand) and runs a YouTube channel (/ @drbradstanfield) with around 250,000 subscribers to explore the latest research and preventive care guidelines.

Host: Nicolás Cherñavsky.
Production: Nicolás Cherñavsky and Nina Torres Zanvettor.
Editing: Nina Torres Zanvettor.
Revision and subtitling: Nicolás Cherñavsky.

============================================================
Notes:
TAME trial website: https://www.afar.org/tame-trial.
Diabetes Prevention Program Outcomes Study (DPPOS): https://repository.niddk.nih.gov/stud…
UK metformin vs sulfonylurea trial on type 2 diabetics: https://www.cmajopen.ca/content/2/3/E162
The New England Journal of Medicine paper on metformin treatment in Covid-19 patients: https://www.nejm.org/doi/full/10.1056…
Lancet paper on metformin treatment in Covid-19 patients: https://www.thelancet.com/journals/la…
Andre Scott’s paper on the cost-effectiveness of treating aging: https://www.nature.com/articles/s4358…
Medical guidelines database mentioned by Brad Stanfield: https://uptodate.com.
============================================================

Heales website (Healthy Life Extension Society): https://heales.org/

Contact e-mail: [email protected].

Continue reading “Metformin and the TAME trial: a conversation with Nir Barzilai and Brad Stanfield” | >

Breakthrough molecule reverses Alzheimer’s symptoms

In a new study, a molecule identified and synthesized by UCLA Health researchers was shown to restore cognitive functions in mice with symptoms of Alzheimer’s disease by effectively jumpstarting the brain’s memory circuitry.

If proven to have similar effects in humans, the candidate compound would be novel among Alzheimer’s disease treatments in its ability to revitalize memory and cognition, study authors said.

There is really nothing like this on the market or experimentally that has been shown to do this.

Replacing Hearts. Restoring Lives

This new titanium heart has a mag lev inside to spin continuously and pump at the same rate as a normal heart.

Heart failure is a global epidemic affecting at least 26 million people worldwide, 6.2 million adults in the U.S., and is increasing in prevalence. Heart transplantations are reserved for those with severe heart failure and are limited to fewer than 6,000 procedures per year globally.

Consequently, the U.S. National Institutes of Health estimated that up to 100,000 patients could immediately benefit from mechanical circulatory support (MCS), and the European market is similarly sized. Without intervention, patients with severe HF have a bleak outlook. For these patients, drug therapy is a limited, relatively ineffective option. Although a heart transplant would meet their needs, only 6,000 donor hearts are available globally each year.

Implantation of a Total Artificial Heart (TAH) is a treatment option for patients with end-stage biventricular HF who need support while on a heart transplant waiting list. Removal of the native ventricles allows the device to completely replace the function of the native heart.

Long COVID Puzzle Pieces are Falling into Place—the Picture is Unsettling

Since 2020, the condition known as long COVID-19 has become a widespread disability affecting the health and quality of life of millions of people across the globe and costing economies billions of dollars in reduced productivity of employees and an overall drop in the work force.

The intense scientific effort that long COVID sparked has resulted in more than 24,000 scientific publications, making it the most researched health condition in any four years of recorded human history.

Long COVID is a term that describes the constellation of long-term health effects caused by infection with the SARS-CoV-2 virus. These range from persistent respiratory symptoms, such as shortness of breath, to debilitating fatigue or brain fog that limits people’s ability to work, and conditions such as heart failure and diabetes, which are known to last a lifetime.

These Scientists Are Battling Dangerous Superbugs With a ChatGPT-Like AI

According to the World Health Organization, antibiotic resistance is a top public health risk that was responsible for 1.27 million deaths across the globe in 2019. When repeatedly exposed to antibiotics, bacteria rapidly learn to adapt their genes to counteract the drugs—and share the genetic tweaks with their peers—rendering the drugs ineffective.

Superpowered bacteria also torpedo medical procedures—surgery, chemotherapy, C-sections—adding risk to life-saving therapies. With antibiotic resistance on the rise, there are very few new drugs in development. While studies in petri dishes have zeroed in on potent candidates, some of these also harm the body’s cells, leading to severe side effects.

What if there’s a way to retain their bacteria-fighting ability, but with fewer side effects? This month, researchers used AI to reengineer a toxic antibiotic. They made thousands of variants and screened for the ones that maintained their bug-killing abilities without harming human cells.

Serotonin changes how people learn and respond to negative information

Increasing serotonin can change how people learn from negative information, as well as improving how they respond to it, according to a new study published in the journal Nature Communications.

The study by scientists at the University of Oxford’s Department of Psychiatry and the National Institute of Health and Care Research (NIHR) Oxford Health Biomedical Research Center (OH BRC) found people with increased serotonin levels had reduced sensitivity to punishing outcomes (for example, losing money in a game) without significantly affecting sensitivity to rewarding ones (winning money).

The study involved 26 participants who were given the drug to increase serotonin, with a further 27 in a , who were asked to do a series of tasks measuring learning and behavioral control. State-of-the-art models were then used to understand participant behavior.

Dr. Ashwin Vasan — Commissioner — NYC Dept. of Health & Mental Hygiene — Strengthening Public Health

Strengthening Public Health Systems For Healthier And Longer Lives — Dr. Ashwin Vasan, Commissioner, NYC Department of Health and Mental Hygiene.

Dr. Ashwin Vasan, MD, PhD is the Commissioner of the New York City Department of Health and Mental Hygiene (https://www.nyc.gov/site/doh/about/ab…).

Dr. Vasan is a primary care physician, epidemiologist and public health expert with nearly 20 years of experience working to improve physical and mental health, social welfare and public policy for marginalized populations here in New York City, nationally and globally. Since 2014 he has served on the faculty at the Columbia University Mailman School of Public Health and Vagelos College of Physicians and Surgeons, and he continues to see patients as a primary care internist in the Division of General Medicine at New York-Presbyterian Hospital/Columbia University Irving Medical Center.

Dr. Vasan most recently served as the President and CEO of Fountain House, a national nonprofit fighting to improve health, increase opportunity, and end social and economic isolation for people most impacted by mental illness. During his tenure, he grew the organization from a New York-based community mental health organization to a national network across eight markets, and grew the budget by nearly $20 million annually. He helped navigate the organization through COVID-19 by driving new telehealth and digital mental health programs while its physical locations closed, as well as developing new community-based outreach and accompaniment programs. Further, Dr. Vasan led the creation of a national policy office in Washington, D.C., working to change national mental health policy on the issues of crisis response services and funding for and quality of community-based mental health services.

From 2016 to 2019, Dr. Vasan served as the founding Executive Director of the Health Access Equity Unit at the NYC Department of Health and Mental Hygiene, which focused on the intersection of clinical and social services for the care of people involved in the justice system and other vulnerable populations — a first-of-its-kind government program in the nation. Under his leadership the team launched the NYC Health Justice Network — an innovative partnership between community-based primary care providers, criminal legal system reentry organizations, the Health Department and the Fund for Public Health — to embed tech-enabled, peer community health workers to promote health and wellness of people reentering the community from incarceration, and their families. The program is currently under evaluation through the CDC Prevention Research Center grant to NYU and CUNY.

Continue reading “Dr. Ashwin Vasan — Commissioner — NYC Dept. of Health & Mental Hygiene — Strengthening Public Health” | >

Epilepsy is first use case for eyelid wearable

The wearables market has been dominated, so far, by smartwatches and fitness trackers. The first Apple Watch was launched in April 2015, and wearable technology now includes jewelry that tracks your steps and notifies you of an incoming call, VR headsets for gamers, earbuds, smart glasses with Internet access, smart clothing integrated with electronic devices and a range of health monitors.

But the world’s first eyelid wearable device opens up a whole new world of opportunity.

Blink Energy’s device weighs just 0.4 grams (0.014 ounces) — less than half the weight of a paperclip – and is fitted to one eyelid. You barely notice it, says Bar-On. “After two minutes you forget it’s there.”

New substrate material for flexible electronics could help combat e-waste

Electronic waste, or e-waste, is a rapidly growing global problem, and it’s expected to worsen with the production of new kinds of flexible electronics for robotics, wearable devices, health monitors, and other new applications, including single-use devices.

A new kind of flexible substrate material developed at MIT, the University of Utah, and Meta has the potential to enable not only the recycling of materials and components at the end of a device’s useful life, but also the scalable manufacture of more complex multilayered circuits than existing substrates provide.

The development of this new material is described in the journal RSC Applied Polymers (“Photopatternable, Degradable, and Performant Polyimide Network Substrates for E-Waste Mitigation”), in a paper by MIT Professor Thomas J. Wallin, University of Utah Professor Chen Wang, and seven others.